Full-Time

Senior Research Associate / Scientist 1

Proteomics Sample Prep

Posted on 8/20/2026

Glyphic Biotechnologies

Glyphic Biotechnologies

11-50 employees

Next-generation protein sequencing platform provider

Compensation Overview

$82k - $129.2k/yr

+ Employee stock options

Berkeley, CA, USA

In Person

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Python
R
Chemical Biology

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Requirements
  • Industry or academic experience relevant to the role and a degree in Proteomics, Chemical Biology, Biochemistry, Analytical Chemistry, or a related field.
  • For Senior Research Associate: a BS or MS with at least 2 years of experience for a BS or 0 years for an MS.
  • For Scientist I: a BS or MS with at least 4 years of experience for a BS or 2 years for an MS.
  • Hands-on experience with liquid chromatography-tandem mass spectrometry-based proteomics.
  • Experience processing precious, complex clinical samples, including tissue dissection and cell pellet handling.
  • Demonstrated experience in sample preparation, protein extraction, and enrichment strategies.
  • Familiarity with data-independent acquisition.
  • Occasional weekend availability for approximately 1-2 hours is required.
Responsibilities
  • Prepare tissue and cell samples for mass spectrometry-based proteomics, including precise tissue dissection and cell pellet processing.
  • Execute established protein and peptide enrichment strategies, including cell-surface labeling and immunopeptidomics workflows.
  • Follow validated protocols for protein extraction and purification across a range of sample types.
  • Use automation to achieve sample throughput at 96x plate-format scale.
  • Learn Orbitrap Astral Zoom operation and troubleshooting.
  • Operate and maintain the Orbitrap Astral Zoom, including routine instrument calibration.
  • Follow established standard operating procedures to ensure consistent and reliable instrument performance.
  • Work with proteomics and cross-functional teams to keep sample processing on schedule.
  • Document methods and maintain standard operating procedures to support consistent, reproducible results.
  • Communicate proactively by surfacing issues early rather than allowing them to emerge downstream.
Desired Qualifications
  • Experience with chemical biology or enrichment strategies.
  • Experience with Thermo Orbitrap mass spectrometers and Vanquish Neo liquid chromatography systems.
  • Experience with cell-surface proteomics or chemical-labeling approaches.
  • Familiarity with immunopeptidomics workflows involving MHC-I or MHC-II.
  • Experience performing liquid chromatography-tandem mass spectrometry on low-input samples, including single-cell, spatial proteomics, or immunopeptidomics samples.
  • Familiarity with high-throughput proteomics workflows, automation, and sample multiplexing.
  • Understanding of protein chemistry, post-translational modifications, and quantitative proteomics.
  • Basic knowledge of bioinformatics tools or scripting, such as R or Python.
Glyphic Biotechnologies

Glyphic Biotechnologies

View

Glyphic Biotechnologies is advancing proteomics by building a next-generation protein sequencing platform. The core product is designed to reveal detailed information about proteins, helping researchers and medical institutions gain new insights into biology and disease. The platform supports sequencing services for researchers and may be licensed to other organizations, generating revenue from service fees and licensing agreements. Unlike many competitors that focus on smaller-scale tools, Glyphic emphasizes a first-of-its-kind sequencing capability for proteins, along with diverse deployment options (serving research labs directly and via licensing). The company's goal is to enable deeper understanding of bodily functions through protein data and to bring its sequencing technology to broader use in the life sciences through services and licensing deals.

Company Size

11-50

Company Stage

Early VC

Total Funding

$43M

Headquarters

New York City, New York

Founded

2021

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Glyphic raised $38 million by September 2025, extending runway for platform development.
  • Glyphic posted multiple 2026 hires in Berkeley, signaling active buildout and execution.
  • NIH and Bakar Labs visibility plus 2025 patent publications validate technical momentum.

What critics are saying

  • Glyphic still sells no commercial platform, so revenue depends on unproven hardware delivery in 2026.
  • Protein sequencing must beat mass spectrometry, or customers ignore Glyphic’s expensive workflow.
  • If ProSE misses accuracy or throughput targets, the 2025 Series A becomes a financing trap.

What makes Glyphic Biotechnologies unique

  • Glyphic’s ProSE sequences proteins de novo, one molecule at a time, without databases.
  • Glyphic claims single-molecule discrimination of all 20 amino acids and PTMs in Berkeley, 2026.
  • Glyphic holds issued patents and a 2025 nanopore peptide-sequencing filing around core chemistry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Paid Maternity and Paternity Leave

Home Office Stipend

Wellness Program

Company Equity

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

0%

2 year growth

3%
Labs of Latvia
Dec 3rd, 2024
Latvian LongeVC invests in US startup Glyphic Biotechnologies

Founded in New York in 2021 by Daniel Estandian and Joshua Yang, Glyphic Biotechnologies is developing a protein sequencing platform that uses single-molecule technology to analyze the sequence of each protein in a complex protein mixture.

BioPharmaTrend
Nov 25th, 2024
LongeVC Invests in Glyphic Biotechnologies

LongeVC has invested in Glyphic Biotechnologies, which is developing single-molecule protein sequencing technology. This innovation surpasses mass spectrometry by enabling precise sequencing of individual proteins in complex mixtures, enhancing protein analysis and broadening applications in drug discovery and diagnostics. The proteomics market, valued at over $30 billion, is set for growth with such advancements. This aligns with LongeVC's mission to support transformative healthcare technologies.

U.S. Securities and Exchange Commission
Feb 21st, 2024
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Johnson & Johnson Innovation
Apr 5th, 2023
Awardees of the BLUE KNIGHT™ Resident QuickFire Challenge Strive Toward Inflection Points | Johnson & Johnson Innovation

By: Rachel Rath, Director, BARDA Alliance, Johnson & Johnson Innovation – JLABS & Ashim Subedee, Director, DRIVe Catalyst Office, BARDA

Bakar Labs
Jan 31st, 2023
Glyphic Biotechnologies Wins $409K SBIR Grant From NIH - Bakar Labs

Congratulations to Glyphic Biotechnologies! NIH recently reported the company had been awarded a $409 SBIR grant for their project "Single-molecule protein sequencing by iterative isolation and identification of N-terminal amino acids." The company is developing and commercializing technology to sequence proteins — instead of DNA. They're hiring!